Trials / Completed
CompletedNCT05631990
A Study to Evaluate the Efficacy and Safety of AD-209
A Randomized, Double-Blind, Parallel, Multi-Center, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of AD-209 in Patients With Essential Hypertension
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 221 (actual)
- Sponsor
- Addpharma Inc. · Industry
- Sex
- All
- Age
- 19 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of AD-209
Detailed description
Condition or disease : hypertension Intervention/treatment Drug : AD-209 Drug : AD-209-1A Drug : AD-209-1B Drug : AD-209-1C Drug : AD-209 Placebo Drug : AD-209-1 Placebo Phase : Phase 2
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AD-209 | PO, Once daily(QD), 8weeks |
| DRUG | AD-209-1A | PO, Once daily(QD), 8weeks |
| DRUG | AD-209-1B | PO, Once daily(QD), 8weeks |
| DRUG | AD-209-1C | PO, Once daily(QD), 8weeks |
| DRUG | AD-209 placebo | PO, Once daily(QD), 8weeks |
| DRUG | AD-209-1 placebo | PO, Once daily(QD), 8weeks |
Timeline
- Start date
- 2023-04-05
- Primary completion
- 2023-11-27
- Completion
- 2023-11-27
- First posted
- 2022-11-30
- Last updated
- 2024-04-05
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05631990. Inclusion in this directory is not an endorsement.